Abstract 1218
Background
Taxanes (TAX) are the current first-line treatment for advanced cutaneous angiosarcoma (CAS). On the other hand, eribulin (ERB) is a nontaxane microtubule inhibitor approved for treatment of advanced sarcoma in Japan. However, no study has evaluated ERB in CAS patients. We hypothesized that ERB would be well tolerated and active in patients with TAX-resistant CAS because TAX and ERB have different mechanisms of action to inhibit microtubule formation.
Methods
We designed a single-arm, prospective observational study of ERB administered at dose of 1.4 mg/m2 on days 1 and 8 in every 21 days. TAX-resistant, advanced CAS patients for whom ERB use was planned were enrolled. The primary endpoint is overall survial (OS), and the secondary endpoint, response ratio (RR), progression-free survival (PFS), and toxicity assessment. The estimated median OS in a previous clinical study (ANGIOTAX), in which patients received TAX as the second-line treatment, was 6 months, so we set this number as the threshold and expected a 6-month OS of 70% with ERB treatment. Based on these numbers, the required number of patients to be enrolled was calculated as 31; thus, we set 35 patients as the target number.
Results
At the time of submissiion, 25 CAS patients, median age 74, were enrolled. All had prior TAX exposure. In all but 1 patient the primary tumor was in the head and neck, and 10 patients had a metastatic tumor. The performance status (PS) was generally good: 22 with PS0 or 1. The median follow-up period was 161 (47-464) days. The respective Kaplan-Meier estimates for OS and PFS rates at 6 months were 70% and 31%. The respective median OS and PFS were not-reached and 94 days. The respective RR at weeks 7, 13, and 25 were 24%, 12% and 11%. No death related to treatment was observed. Although 9 patients experienced >grade 3 toxicity (7, neutropenia; 2, anemia; 1, retroperitoneal abscess), they all recovered.
Conclusions
ERB is a well-tolerated regimen with promising activity in TAX-resistant CAS. The common toxicity is neutropenia, which requires growth factor support. This study is underway and enrollment is expected to be completed in 2018. This study may provide a new treatment option for patients with PTX-resistant CAS.
Clinical trial identification
UMIN000023331.
Legal entity responsible for the study
University of Tsukuba.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract